THE EFFECT OF RITONAVIR ON THE PHARMACOKINETICS OF MEPERIDINE IN HIV-NEGATIVE SUB
THE EFFECT OF RITONAVIR ON THE PHARMACOKINETICS OF MEPERIDINE IN HIV-NEGATIVE SUB
批准号:
6103662
负责人:
STEPHEN PISCITELLI
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
人类免疫缺陷病毒(HIV)感染的患者可能需要服用度冷丁来控制疼痛或寒战,以及与白细胞介素2或两性霉素B相关的强直。利托那韦(Norvir)是一种蛋白酶抑制剂,是参与药物新陈代谢的主要酶系统细胞色素P-450的有效抑制剂。从理论上讲,利托那韦和度冷丁的联合应用可能导致度冷丁浓度和毒性增加,因此,禁止同时使用它们。这项研究将描述8名HIV阴性的健康患者的度冷丁及其主要代谢物去甲度冷丁的药代动力学。受试者将在研究的第0天接受50毫克剂量的PO度冷丁。将在48小时内连续采集样本,以确定度冷丁和去甲度冷丁的浓度。利托那韦将在第2天开始使用,并在5天内逐步增加到500毫克,BID。在总共服用利托那韦10天后,将再次给予50毫克PO剂量的度冷丁,并将在72小时内采集样本,同时继续服用利托那韦整个采样期。比较两组的最大血液量、达到最大血液量的时间、曲线下面积和清除量。这项研究将提供服用联合利托那韦的患者的度冷丁处置数据。目前,已完成学科招生和学习,正在进行数据分析。结果:在所有受试者中,度冷丁的AUC值在RTV存在的情况下平均降低了674%(p<;0.005)。去甲度冷丁的平均AUC增加了47%,表明诱导了肝脏代谢。RTV暴露剂量与以往报道相似,CL/F平均值为5.6 L/h。结论:与RTV相伴的度冷丁AUC显著减少而不是增加。根据这些发现,这种组合产生与麻醉剂相关的不良反应的风险似乎微乎其微。这表明在RTV治疗中不需要使用度冷丁的禁忌症。这项研究结束了。
英文摘要
Human immunodeficiency virus (HIV)-infected patients may require administration of meperidine for pain control or chills and rigors associated with interleukin-2 or amphotericin B. Ritonavir (Norvir) is a protease inhibitor that is a potent inhibitor of cyto-chrome P-450, the major enzyme system involved in drug metabolism. The combination of ritonavir and meperidine could theoretically lead to increased meperidine concentrations and toxicity, and thus, their concomitant administration is contraindicated. This study will characterize the pharmacokinetics of meperidine and its major metabolite, nor- meperidine, in eight HIV-negative, healthy patients. Subjects will receive a 50 mg dose of PO meperidine on day 0 of the study. Serial samples will be drawn over 48 hours for determination of meperidine and nor-meperidine concentrations. Ritonavir will be initiated on day 2 and escalated to a dose of 500 mg BID over 5 days. After a total of 10 days of ritonavir, a 50 mg PO dose of meperidine will again be administered and samples will be collected over 72 hours while continuing ritonavir through the sampling period. Maximum blood level, time to maximum blood level, area under the curve, and clearance will be compared between the two groups. The study will provide data on meperidine disposition in patients receiving concomitant ritonavir. Currently, subject enrollment and study has been completed and data are being analyzed. Results: The AUC of meperidine decreased in all subjects by a mean of 67 ? 4 percent in the presence of RTV (p<0.005). Normeperidine mean AUC was increased 47 percent suggesting induction of hepatic metabolism. RTV exposure was similar to previous reports with 500 mg BID doses, CL/F averaged 5.6 L/h. Conclusions: Meperidine AUC is significantly reduced not increased, by concomitant RTV. Based on these findings, the risk of narcotic-related adverse effects from this combination appears to be minimal. This suggests that contraindication of meperidine is not necessary during RTV therapy. This study is terminated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACOKINETICS OF BID VERSUS QID DOSING OF SULFADIAZINE IN HIV-INFECTED PATIENT
-
批准号:6289452
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patien
-
批准号:6431831
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patient
-
批准号:6103663
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
EFFECT OF GARLIC ON PHARMACOKINETICS OF SAQUINAVIR
-
批准号:6414325
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
海外基金